Related Experiment Video

Updated: Aug 10, 2026

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa

M J Haverkorn1

  • 1Laboratory for Medical Microbiology, Endhoven, The Netherlands.

Pharmaceutisch Weekblad. Scientific Edition
|December 11, 1987
PubMed

Insights

Oral ciprofloxacin treatment for Pseudomonas aeruginosa bronchitis showed limited success, with many patients experiencing persistent or recurring infections. Hospital-acquired infections demonstrated a better response to ciprofloxacin.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Bronchitis caused by Pseudomonas aeruginosa presents a significant treatment challenge.
  • Ciprofloxacin is a fluoroquinolone antibiotic commonly used for bacterial infections.

Purpose of the Study:

  • To evaluate the efficacy of oral ciprofloxacin in treating bronchitis caused by Pseudomonas aeruginosa.
  • To assess the impact of risk factors, including hospital-acquired infections, on treatment outcomes.
  • To investigate changes in Pseudomonas aeruginosa susceptibility to ciprofloxacin during and after treatment.

Main Methods:

  • A cohort of 31 patients with Pseudomonas aeruginosa bronchitis received oral ciprofloxacin.
  • Patient data included presence of permanent and transient risk factors and history of hospital-acquired infection.
  • Clinical outcomes (cure rates) and microbiological data on Pseudomonas aeruginosa persistence/recurrence and in vitro susceptibility were recorded.

Main Results:

  • Only 16 out of 31 patients achieved a complete or partial cure.
  • Pseudomonas aeruginosa persisted or recurred in 19 patients.
  • Patients with hospital-acquired infections showed better outcomes compared to others.
  • A significant decrease in in vitro susceptibility of persisting Pseudomonas aeruginosa strains to ciprofloxacin was observed, with a tendency for recovery after treatment cessation.

Conclusions:

  • Oral ciprofloxacin demonstrates limited efficacy in eradicating Pseudomonas aeruginosa from bronchitis patients.
  • Hospital-acquired Pseudomonas aeruginosa infections may respond differently to ciprofloxacin.
  • Treatment with ciprofloxacin can lead to decreased susceptibility in persisting bacterial strains, highlighting the need for careful monitoring and alternative therapeutic strategies.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Related Concept Videos

Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...